Guido Grentzmann

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.

Interpharma Investments Ltd. operates as a holding company with interest in the distribution and manufacturing of pharmaceutical products. It provides product development, planning and procurement, and commercial manufacturing services. It also offers marketing services and support solutions to the pharmaceutical companies. The company is headquartered in Hong Kong.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts.

Proteros biostructures GmbH is a holding company which serves as a discovery service business. Its business areas are Discovery Pipeline, Discovery Services and Science & Technology. The Discovery Pipeline focuses on protein biochemistry, X-ray crystallography, biophysics, computational chemistry and property driven medicinal chemistry, Discovery Services offers drug discovery services with expertise and proprietary technologies for protein production, protein structure analysis, kinetic and thermodynamic profiling and Science & Technology segment focuses on industrialized structure-guided lead development infrastructure. The company was founded by Robert Huber and Torsten Neuefeind in 1999 and is headquartered in Martinsried, Germany.

Bayer HealthCare Pharmaceuticals, Inc. manufactures pharmaceutical drugs. It offers pharmaceuticals and therapeutics in the areas of diagnostic imaging, hematology and cardiology, cancer, women's health and several other chronic diseases such as multiple sclerosis and Parkinson's disease. Bayer HealthCare Pharmaceuticals was founded in 1979 and is located in Wayne, NJ.

Bayer CropScience AG manufactures and distributes pesticides, and vegetable seeds. Its products include crops such as cotton, fruits and vegetables, oil seeds and wheat, brands includes fungicides, herbicides and seeds growth. The company was founded in 1979 and is headquartered In Monheim am Rhein, Germany.

Affidea Group BV provides diagnostic and renal care services. It is a medical service provider that offers diagnostic investigations, renal care, clinical laboratories, cancer treatment, and teleradiology services. The firm also operates centers for dialysis, diagnostic, and cancer treatment purposes. The company was founded in 1991 and is headquartered in Amsterdam, the Netherlands.

Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education.

SYNLAB International GmbH offers medical laboratory services for practicing doctors, clinics and the pharmaceutical industry. It offers medical instruments, transfusion medicines, cytology, pathology, human genetics, and general hygiene services. The company was founded by Bartl Wimmer in 1998 and is headquartered in Munich, Germany.

Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom.

Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland.

OM Pharma SA engages in manufacture of pharmaceutical products. Its portfolio includes products for respiratory tract infections, lower urinary tract infections, chronic venous insufficiency, microangiopathies, hemorrhoids, and menometrorrhagia. The company was founded by Jean-Rene Ricard in 1937 and is headquartered in Meyrin, Switzerland.

Soho Flordis International Pty Ltd. manufactures natural medicine products. Its brands include flordis, ProThera, COMPLEMENTARY, ginsana and KLAIRE LABS. Its products include ginsana, keenmind, nuvexa and gincosan. The company was founded in 2010 and is headquartered in St. Leonards, Australia.

Galenica AB develops and manufactures pharmaceutical drugs. It offers service to partners for the development of oral, dermal, nasal, rectal, pulmonary and parenteral formulations of small molecules to peptides/proteins and biologics. The company was founded in 1999 and is headquartered in Malmo, Sweden.

Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.

iolite Capital Management AG is an investment firm that was founded in 2008. The company is based in Zug, Switzerland. The Swiss company invests in mostly public companies with significant unrecognized value. The company applies an opportunistic, research-driven process that combines the best elements of private equity and public market investing. The company was founded in 2008 by Robert Leitz. Robert Leitz has been the CEO since 2008.